AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
Clobazam demonstrates consistent efficacy as adjunctive therapy in pediatric drug-resistant epilepsy, with the strongest evidence supporting its use in LGS.
Coenfy (xanomeline–trospium), approved by the U.S. Food and Drug Administration in 2024, represents the first antipsychotic with a non-dopaminergic mechanism of action and expands current treatment options by introducing a novel cholinergic therapeutic strategy.
Clozapine remains the gold-standard treatment for refractory schizophrenia, yet its use in older adults is often limited by concerns regarding tolerability, age-related pharmacokinetic changes, and the burden of medical comorbidities. This narrative review synthesises current evidence on clozapine use in older populati...
Background : Acute neonatal seizures are among the most common neurological emergencies during the neonatal period and are associated with increased mortality and long-term neurodevelopmental impairment. Phenobarbital has remained the conventional first-line antiseizure medication because of its rapid onset of acti...
PGx-guided individualized treatment has significant advantages for depression; this study offers evidence-based support for precision individualized antidepressant pharmacotherapy and assists clinical medication decision-making.
Background: Drug-resistant epilepsy (DRE) affects approximately one-third of individuals with epilepsy, where seizures remain uncontrolled despite appropriate trials of at least two antiseizure medications (ASMs). Neuroinflammation, specifically chronic microglial activation, plays an important role in epileptogenesis,...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.